Therapy | Page 154 of 190 | SpiritIndia.com

Multiple Myeloma :: Long-term therapy in the fight against multiple myeloma cancer

There is no known cure for multiple myeloma, so its diagnosis means high-dose chemotherapy followed by repeated treatments with each relapse of the cancer ? a watch and wait approach. A new approach of providing patients with continuous therapy to keep the cancer at bay was explored by a team of international researchers from France, Switzerland, and Belgium; their findings will be published in the November 15, 2006, issue of Blood, the official journal of the American Society of Hematology.

Health :: Columbia research explores impact of gum disease therapy on pregnancy

A study published in the New England Journal of Medicine shows that treatment for periodontal disease in pregnant women does not result in a lower rate of adverse pregnancy outcomes such as preterm birth and low birth weight. At the same time, the study showed that periodontal treatment during pregnancy is safe. The researchers recommend additional studies to assess the potential benefits of the treatment.

Menopause :: Pituitary hormone in menopause under study

An interdisciplinary research team led by Dr. Joe Cannon (third from right) will examine the effects of follicle stimulating hormone on white blood cells. Future studies may lead to alternatives… Click here for more information. Regulating a hormone abundant in women approaching menopause could offer alternatives for hormone replacement therapy, Medical College of Georgia researchers say.

Lung Transplant :: Proteins may predict lung transplant rejection

Researchers have identified three proteins that appear to be highly predictive of chronic lung rejection up to 20 months before the rejection occurred. Lung transplants are a common therapy for many end-stage lung diseases such as chronic obstructive pulmonary disease, cystic fibrosis and pulmonary hypertension. If doctors can predict which patients are beginning to reject the transplanted organ, they could try to head it off.

Health :: Australians will have access to better, more affordable mental health care

Australians will have access to better, more affordable mental health care through new Medicare mental health items and support services costing $538 million over five years. The new MBS items for mental health will make Medicare rebates available for GPs who provide early intervention, assessment and management of patients with mental disorders as part of a GP Mental Health Care Plan.

Nutrition :: Coenzyme Q10 – Should you take this supplement?

You may have heard claims that the supplement coenzyme Q10 can lower blood pressure, boost the immune system and improve certain heart diseases. There are also claims it can help fight cancer, Parkinson’s disease, wrinkles, diabetes, gum diseases and many other problems.

Health :: Intact Tonsils Triple Risk of Recurrent Strep Throat

Children with recurrent strep throat whose tonsils have not been removed are over three times more likely to develop subsequent episodes of strep throat than children who undergo tonsillectomy, according to a Mayo Clinic study published in the Nov. 2 issue of Laryngoscope.

Dental Health :: Study Finds Periodontal Treatment Does Not Lower Preterm Birth Risk

Scientists supported by the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health, report in this week?s New England Journal of Medicine that pregnant women who received non-surgical treatment for their periodontal, or gum, disease did not also significantly lower their risk of delivering a premature or low-birthweight baby.

Health :: New treatment for Pompe disease – Glycogen storage disease type 2

Patients with a potentially fatal disease are being offered the UK?s first treatment for the condition at the Royal Free. Pompe disease is a neuro-muscular disorder caused by an enzyme deficiency. The lysosomal storage disorders unit at the hospital recently began a programme using Myozyme, the first licensed enzyme replacement therapy for this condition.

Health :: Pharmion enrolled first patient into Vidaza Patient Registry

Pharmion Corporation (Nasdaq: PHRM) announced today the enrollment of the first patient in AVIDA(TM), a registry for patients treated with Vidaza(R) (azacitidine for injectable suspension). Vidaza was approved in May 2004 for the treatment of all five French-American-British (FAB) subtypes of myelodysplastic syndromes (MDS): refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). Myelodysplastic syndromes are a serious and life-threatening group of diseases in which the bone marrow does not function normally, resulting in the production of malformed or immature blood cells.